SK Bioscience and GSK start Phase 3 trial of an adjuvanted COVID-19 vaccine candidate
Advance to Phase 3 follows positive interim Phase 1/2 immunogenicity and safety data. The global clinical trial will evaluate vaccine candidate GBP510 against the AZ/Oxford COVID-19 vaccine